The SEER Inquiry System (SINQ) is a searchable collection of questions that cancer registrars have had while coding cancer cases. These are questions submitted by designated registrars in SEER registries. The questions are answered by expert staff and go through a rigorous review process by NCI SEER staff and designated SEER registry staff before being added to SINQ.

Click Search to look for specific questions in SINQ or to select questions for a Report.

If you cannot find an answer to your question, refer to the Ask a SEER Registrar page.

Recent Questions
<< First    < Prev 10    11 to 20 of 2073    Next 10 >    Last >>
Add to Report ID Question Status Last Updated

EOD 2018/Summary Stage 2018--Brain and CNS: What are the Extent of Disease (EOD) Primary Tumor, EOD Reg Nodes, and Summary Stage 2018 codes for intradural schwannoma of the lumbar spine (L2-L4)? See Discussion.

Final Jan 02 2019

Solid Tumor Rules (2018)/Histology--Lung:  What is the histology code of a 2018 lung cancer case with invasive non-mucinous adenocarcinoma?  For non-mucinous carcinoma/adenocarcinoma, the Solid Tumor Rules have codes for microinvasive, minimally invasive, preinvasive, and in situ. Do we default to the microinvasive/minimally invasive code?

Final Dec 20 2018

Solid Tumor Rules (2018)/Histology--Lung: What is the histology code of a non-small cell lung cancer (NSCLC), NOS as this is not on the AJCC list of histologies?  See Discussion. 

Final Dec 20 2018

Reportability/Histology--Appendix: Is high grade appendiceal mucinous neoplasm (HAMN) diagnosed in 2018 reportable? See Discussion.

Final Dec 20 2018

Solid Tumor Rules (2018)/Histology--Lung: What is the histology code of a 2018 lung case whose pathology states adenocarcinoma, acinar predominant?

Final Dec 20 2018

Date of diagnosis/Ambiguous terminology--Cervix Uteri: Is the date of diagnosis of a cervical pap smear done in December 2017, that states high-grade squamous intraepithelial lesion with features suspicious for invasion, followed by a cervical biopsy in 2018 positive for squamous cell carcinoma, in 2017? Is the ambiguous term used in the cytology in 2017 (suspicious for invasion) to determine diagnosis as the SEER manual states to use the ambiguous cytology as the date of diagnosis if confirmed later.

Final Dec 20 2018

Solid Tumor Rules (2018)/Histology--Lung:  What is the correct histology of a lung mass with a CT-directed fine needle aspirate–positive for malignancy, favor squamous cell carcinoma. See Discussion.

Final Dec 20 2018

Solid Tumor Rules (2018)/Histology--Lung: If the pathology states non-small cell carcinoma of the lung (NSCLC), consistent with squamous cell carcinoma, is the code non-small cell carcinoma according to the Solid Tumor Rules? The Medical Oncologist states that the tumor is a squamous cell carcinoma. In these instances would you code the squamous cell carcinoma since you have a definite physician statement?

Final Dec 20 2018

First Course Treatment--Other Therapy: Please explain how to code this new therapy, peptide receptor radionuclide therapy (PRRT) for rare neuroendocrine tumors.  See Discussion.

Final Dec 03 2018

2018 Solid Tumor Rules/Histology--Lung:  What is the appropriate histology code for the case below in the Discussion section? Is there a difference between adenocarcinoma in situ (bronchioloalveolar carcinoma), non-mucinous type (8252/2) and adenocarcinoma in-situ, mucinous? See Discussion.

Final Nov 29 2018
< Prev 10    Next 10 >